Next Article in Journal
Biosynthesis of Polyunsaturated Fatty Acids in Octopus vulgaris: Molecular Cloning and Functional Characterisation of a Stearoyl-CoA Desaturase and an Elongation of Very Long-Chain Fatty Acid 4 Protein
Previous Article in Journal
Marine Diterpenes: Molecular Modeling of Thrombin Inhibitors with Potential Biotechnological Application as an Antithrombotic
Previous Article in Special Issue
Marine Algae as a Potential Source for Anti-Obesity Agents
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives

1
Clinical and Molecular Epidemiology, IRCSS San Raffaele Pisana, Via di Valcannuta 247, I-00166 Rome, Italy
2
Department of Pulmonary Rehabilitation, IRCCS San Raffaele Pisana, Via della Pisana 235, I-00163 Rome, Italy
3
Scientific Direction, IRCSS San Raffaele Pisana, Via di Valcannuta 247, I-00166 Rome, Italy
*
Author to whom correspondence should be addressed.
Mar. Drugs 2017, 15(3), 81; https://doi.org/10.3390/md15030081
Submission received: 22 November 2016 / Revised: 23 February 2017 / Accepted: 15 March 2017 / Published: 20 March 2017
(This article belongs to the Special Issue Marine Natural Products that Target Metabolic Disorders)

Abstract

Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).
Keywords: chronic obstructive pulmonary disease; comorbidities; management strategy; marine compound; metabolic disorder; inflammation; systems approaches chronic obstructive pulmonary disease; comorbidities; management strategy; marine compound; metabolic disorder; inflammation; systems approaches

Share and Cite

MDPI and ACS Style

Lamonaca, P.; Prinzi, G.; Kisialiou, A.; Cardaci, V.; Fini, M.; Russo, P. Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. Mar. Drugs 2017, 15, 81. https://doi.org/10.3390/md15030081

AMA Style

Lamonaca P, Prinzi G, Kisialiou A, Cardaci V, Fini M, Russo P. Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. Marine Drugs. 2017; 15(3):81. https://doi.org/10.3390/md15030081

Chicago/Turabian Style

Lamonaca, Palma, Giulia Prinzi, Aliaksei Kisialiou, Vittorio Cardaci, Massimo Fini, and Patrizia Russo. 2017. "Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives" Marine Drugs 15, no. 3: 81. https://doi.org/10.3390/md15030081

APA Style

Lamonaca, P., Prinzi, G., Kisialiou, A., Cardaci, V., Fini, M., & Russo, P. (2017). Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. Marine Drugs, 15(3), 81. https://doi.org/10.3390/md15030081

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop